Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 19NIH 3NETWORK 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Refractory Differentiated Thyroid Gland Carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 138Cyclophosphamide 108Cisplatin 103Doxorubicin 99Vincristine 76Filgrastim 60Etoposide 58Paclitaxel 56Carboplatin 53Fluorouracil 51Methotrexate 49Dexamethasone 49Cytarabine 43Prednisone 42Leucovorin 40Granulocyte Colony-Stimulating Factor 34Docetaxel 34Radiation 31Specimen Handling 30Tamoxifen 27Daunorubicin 27Magnetic Resonance Spectroscopy 26Calcium Dobesilate 26Ifosfamide 25Mercaptopurine 24Gemcitabine 24Platinum 22Goserelin 221,2-diaminocyclohexaneplatinum II citrate 22Chemotherapy, Adjuvant 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NETWORK × cabozantinib × Clear all
NCT06475989 2026-05-15

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Eastern Cooperative Oncology Group

Phase 3 Recruiting
264 enrolled
Head & Neck

Refractory Differentiated Thyroid Gland Carcinoma

NCT07383441 2026-02-03

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

SWOG Cancer Research Network

Phase 3 Not yet recruiting
718 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡